Shares of Merck & Co. Inc. MRK rallied 2.08% to $89.50 Friday, on what proved to be an all-around rough trading session for ...

Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant.

HEIDELBERG, Germany, February 06, 2025 / Biotech Newswire / --German independent research institute BioMed X announces the successful completion of its oncology research project in partnership with ...

Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Company (MRK – Research Report) yesterday and set a price target of $110.00. The company’s shares closed yesterday at $89.67.

Robert Davis; Chairman of the Board, President, Chief Executive Officer; Merck & Co Inc Caroline Litchfield; Chief Financial Officer, Executive Vice President; Merck & Co Inc Dean Li; Executive ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

Robert Davis; Chairman of the Board, President, Chief Executive Officer; Merck & Co Inc Caroline Litchfield; Chief Financial Officer, Executive Vice President; Merck & Co Inc Dean Li; Executive Vice ...